1.87
Precedente Chiudi:
$1.77
Aprire:
$1.86
Volume 24 ore:
119.10K
Relative Volume:
0.07
Capitalizzazione di mercato:
$4.22M
Reddito:
-
Utile/perdita netta:
$-6.91M
Rapporto P/E:
-0.5736
EPS:
-3.26
Flusso di cassa netto:
$-6.14M
1 W Prestazione:
-14.61%
1M Prestazione:
+6.86%
6M Prestazione:
-36.39%
1 anno Prestazione:
-50.54%
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Nome
Galmed Pharmaceuticals Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GLMD con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
GLMD
Galmed Pharmaceuticals Ltd
|
1.87 | 4.00M | 0 | -6.91M | -6.14M | -3.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2020-05-22 | Downgrade | B. Riley FBR | Buy → Neutral |
2020-02-04 | Iniziato | Craig Hallum | Buy |
2020-01-30 | Ripresa | Cantor Fitzgerald | Overweight |
2019-12-02 | Iniziato | Canaccord Genuity | Buy |
2018-12-12 | Iniziato | B. Riley FBR | Buy |
2018-08-02 | Reiterato | Maxim Group | Buy |
2018-07-13 | Iniziato | Stifel | Buy |
2018-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
2018-06-12 | Reiterato | H.C. Wainwright | Buy |
2018-03-15 | Aggiornamento | Maxim Group | Hold → Buy |
2018-02-14 | Downgrade | Maxim Group | Buy → Hold |
2018-02-12 | Reiterato | H.C. Wainwright | Buy |
2017-11-15 | Iniziato | ROTH Capital | Buy |
2017-08-08 | Reiterato | H.C. Wainwright | Buy |
2017-07-31 | Reiterato | Maxim Group | Buy |
2016-08-01 | Reiterato | Maxim Group | Buy |
2016-07-06 | Ripresa | ROTH Capital | Buy |
2016-03-28 | Ripresa | H.C. Wainwright | Buy |
2015-06-23 | Iniziato | H.C. Wainwright | Buy |
2015-05-06 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
Mostra tutto
Galmed Pharmaceuticals Ltd Borsa (GLMD) Ultime notizie
What analysts say about Galmed Pharmaceuticals Ltd. stockFree Stock Market Beginners Guide - Autocar Professional
Galmed Pharmaceuticals Ltd. Stock Analysis and ForecastMarket-crushing stock picks - Autocar Professional
What drives Galmed Pharmaceuticals Ltd. stock priceMassive stock growth - jammulinksnews.com
Is Galmed Pharmaceuticals Ltd. a good long term investmentTurbocharged investment results - jammulinksnews.com
The Role of News and Events in Galmed Pharmaceuticals Ltd Inc. (GLMD) Price Performance - investchronicle.com
Why India’s Pharmaceutical Stocks Are on the Rise High Accuracy Trade SignalsRapid market gains - PrintWeekIndia
Solara Active Pharma Sciences Limited (SOLARAPP)’s Trend in 2025Free Stock Market Forecast Reports - jammulinksnews.com
PLAB Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
What makes Galmed Pharmaceuticals Ltd. stock price move sharplyFree Insider Trading Tips - Newser
Why Galmed Pharmaceuticals Ltd. stock attracts strong analyst attentionSafe and Scalable Investment Tips - Newser
How Galmed Pharmaceuticals Ltd. stock performs during market volatilitySteady Profit Stock Forecasts - Newser
Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond Nash - marketscreener.com
Galmed Pharmaceuticals Unveils Biomarker Signature for Aramchol, Expanding Market Potential - TipRanks
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH - Longview News-Journal
Wall Street Zen Upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) to Sell - Defense World
Galmed Pharmaceuticals: Q1 Earnings Snapshot - New Haven Register
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Galmed Pharmaceuticals Reports Q1 2025 Financial Results and Advances in Oncology - TipRanks
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World
Galmed Pharmaceuticals Unveils Promising Aramchol Results in PSC Models - TipRanks
Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramc - GuruFocus
Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramchol in Treating PSC | GLMD Stock News - GuruFocus
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models - PR Newswire
Galmed Pharmaceuticals Ltd Azioni (GLMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):